Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07518147) titled 'A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment' on April 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Condition:
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Intervention:
Drug: BL-M05D1
Drug: Paclitaxel
Drug: Docetaxel
Recruitme...